I read this data from an Italian website as being positive.

Looks like compared to the placebo, the p value was extremely low, while the placebo and control were no different by T test.

This would be great. I had to clean this up coding wise and it was pretty raw. The nice version has not been announced yet, but this is public record info Bioelectronic investors should be aware of.

Rather than bitch, I am just correcting the situation.

Standard Deviation

Baseline-TotalBaselineRptGroup

10.9

67.7

Baseline-BaselineRptGroup.1

11.9

68.6

Baseline-BaselineRptGroup.2

10

66.9

Mean
Age, Continuous

years

Not Applicable

Baseline-TotalBaselineRptGroup

42

Baseline-BaselineRptGroup.1

21

Baseline-BaselineRptGroup.2

21

Female

Baseline-TotalBaselineRptGroup

18

Baseline-BaselineRptGroup.1

9

Baseline-BaselineRptGroup.2

9

Male

Number
Gender, Male/Female

participants

Not Applicable

Baseline-TotalBaselineRptGroup

60

Baseline-BaselineRptGroup.1

30

Baseline-BaselineRptGroup.2

30

Italy

Number
Region of Enrollment

participants

emitting group
Wearable pulsed electromagnetic fields

30

Active

non emitting device
Wearable pulsed electromagnetic fields

30

Placebo

60

Total

No

No

2015-01-22T10:44:26-05:00

Standard Deviation

OutcomeMeasure.1-OutcomeRptGroup.1

16

67

OutcomeMeasure.1-OutcomeRptGroup.2

15

63.6

VAS (baseline)

OutcomeMeasure.1-OutcomeRptGroup.1

16

50

OutcomeMeasure.1-OutcomeRptGroup.2

15

61

VAS (after 1 month of treatment)

visual analogue scale (VAS) is a validated self report instrument assessing self report pain intensity
Possible scores ranges:from 0 (no pain) to 100 (the maximum of pain)

Mean

baseline and 4 weeks

Change From Baseline in Pain Perception Measured on Visual Analog Score (VAS) at Week 4

units on a scale

Primary

OutcomeMeasure.1-OutcomeRptGroup.1

2-Sided

<0.0001

t-test, 2 sided

No

OutcomeMeasure.1-OutcomeRptGroup.2

2-Sided

>0.05

t-test, 2 sided

No

emitting group
Wearable pulsed electromagnetic fields

30

Active

non emitting device
Wearable pulsed electromagnetic fields

30

Placebo

Posted

No

Standard Deviation

OutcomeMeasure.3-OutcomeRptGroup.1

49

136

OutcomeMeasure.3-OutcomeRptGroup.2

40.8

129.2

WOMAC total (baseline)

OutcomeMeasure.3-OutcomeRptGroup.1

48

111

OutcomeMeasure.3-OutcomeRptGroup.2

39

126

WOMAC total (4 weeks)

Multi-item questionnaire used to assess pain, stiffness, and physical function in patients with knee osteoarthritis.
The WOMAC consists of 24 items divided into 3 subscales:
Pain (5 items), Stiffness (2 items) and Physical Function (17 items).
Score Range: On the Likert Scale version, the scores are summed for items in each subscale, with possible ranges as follows: pain=0-50, stiffness=0-20, physical function=0-170. A total WOMAC score is created by summing the items for all three subscales. A higher score represents a worse outcome.

Mean

baseline and 4 weeks

Changes From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 4

units on a scale

Primary

OutcomeMeasure.3-OutcomeRptGroup.1

2-Sided

=0.0001

t-test, 2 sided

No

OutcomeMeasure.3-OutcomeRptGroup.2

2-Sided

>0.05

t-test, 2 sided

No

emitting group
Wearable pulsed electromagnetic fields

30

Active

non emitting device
Wearable pulsed electromagnetic fields

30

Placebo

Posted

No

emitting group
Wearable pulsed electromagnetic fields

Active

non emitting device
Wearable pulsed electromagnetic fields

Placebo

ParticipantFlow-ParticipantFlowGroup.1

30

ParticipantFlow-ParticipantFlowGroup.2

30

ParticipantFlow-ParticipantFlowGroup.1

3

ParticipantFlow-ParticipantFlowGroup.2

3

Lost to Follow-up

3

ParticipantFlow-ParticipantFlowGroup.1

3

ParticipantFlow-ParticipantFlowGroup.2

ParticipantFlow-ParticipantFlowGroup.1

33

ParticipantFlow-ParticipantFlowGroup.2

33

Overall Study

gianbagnato@gmail.com

University of Messina

00390902212502
Gianfilippo Bagnato

RELEASED

0

emitting group
Wearable pulsed electromagnetic fields

0

0

30
30
Active

non emitting device
Wearable pulsed electromagnetic fields

0

0

30
30
Placebo

51

 

Advertisements